Literature DB >> 15459674

New drugs for asthma.

Peter J Barnes1.   

Abstract

Asthma is a major and increasing global health problem and, despite major advances in therapy, many patients' symptoms are not adequately controlled. Treatment with combination inhalers, which contain a corticosteroid and long-acting beta(2) adrenoceptor agonist, is the most effective current therapy. There is therefore a search for new therapies, particularly safe and effective oral treatments and those that are more efficacious in severe asthma. New therapies in development include mediator antagonists and inhibitors of cytokines, although these therapies might be too specific to be very effective. New anti-inflammatory therapies include corticosteroids and inhibitors of phosphodiesterase-4, p38 mitogen-activated protein kinase and nuclear factor-kappaB. The prospects for a curative treatment are on the horizon.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15459674     DOI: 10.1038/nrd1524

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  50 in total

1.  A novel EST-derived RNAi screen reveals a critical role for farnesyl diphosphate synthase in β2-adrenergic receptor internalization and down-regulation.

Authors:  Xiaofeng Jiang; Hui Pan; Joseph F Nabhan; Ramaswamy Krishnan; Cynthia Koziol-White; Reynold A Panettieri; Quan Lu
Journal:  FASEB J       Date:  2012-01-25       Impact factor: 5.191

Review 2.  Cytokine and anti-cytokine therapy for asthma.

Authors:  Hans-Uwe Simon
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

3.  Drugs for asthma.

Authors:  Peter J Barnes
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  Collagen impairs glucocorticoid actions in airway smooth muscle through integrin signalling.

Authors:  J V Bonacci; M Schuliga; T Harris; A G Stewart
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

5.  Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function.

Authors:  Marco Idzko; Hamida Hammad; Menno van Nimwegen; Mirjam Kool; Tobias Müller; Thomas Soullié; Monique A M Willart; Daniëlle Hijdra; Henk C Hoogsteden; Bart N Lambrecht
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

Review 6.  Pharmacotherapy of asthma.

Authors:  Martin M Zdanowicz
Journal:  Am J Pharm Educ       Date:  2007-10-15       Impact factor: 2.047

Review 7.  Mechanistic systems biology of inflammatory gene expression in airway smooth muscle as tool for asthma drug development.

Authors:  Chi-Ming Hai
Journal:  Curr Drug Discov Technol       Date:  2008-12

8.  Uncontrolled airway inflammation in lung disease represents a defect in counter-regulatory signaling.

Authors:  Anna Planaguma; Bruce D Levy
Journal:  Future Lipidol       Date:  2008

9.  Carbonic anhydrase IV is expressed on IL-5-activated murine eosinophils.

Authors:  Ting Wen; Melissa K Mingler; Benjamin Wahl; M Eyad Khorki; Oliver Pabst; Nives Zimmermann; Marc E Rothenberg
Journal:  J Immunol       Date:  2014-05-07       Impact factor: 5.422

10.  Eosinophil adoptive transfer system to directly evaluate pulmonary eosinophil trafficking in vivo.

Authors:  Ting Wen; John A Besse; Melissa K Mingler; Patricia C Fulkerson; Marc E Rothenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.